Valuation Trading Multiples & Precedent Transactions: RNA and Peptide Therapeutics Companies
Valuation benchmarks for RNA and Peptide Therapeutics Companies. Access public trading comps, EV/EBITDA acquisition multiples, and private market data for pitch books and valuation analysis.
1.1 - RNA and Peptide Therapeutics Companies Market Context & Valuation Drivers
Companies in this trading comparables group develop, manufacture, and commercialize RNA- and peptide-based therapeutics, alongside select small-molecule specialty drugs and related diagnostics. Business models span commercial-stage biopharma product sales, licensing and royalty agreements, and GMP peptide/oligonucleotide contract manufacturing. They are grouped together as valuation benchmarks due to shared modality focus, clinical and regulatory pathways, and revenue exposure to innovative oncology, neurology, immunology, and infectious disease treatments.
Typical capabilities include discovery and clinical development of antisense oligonucleotides and peptide therapeutics, commercial manufacturing of GMP peptide and oligonucleotide active pharmaceutical ingredients, scale-up and process development, regulatory submissions and post-marketing surveillance, and global commercialization through specialty salesforces and distribution partners. Many also provide molecular diagnostics and genetic testing services, out-licensing and co-development partnerships, and managed access programs across oncology, neurology, immunology, cardio-renal, and infectious disease indications.
Primary customers include hospital systems and healthcare providers prescribing specialty therapies, biopharma sponsors procuring peptide and oligonucleotide manufacturing, and diagnostic labs deploying molecular tests. Valuation drivers center on net sales growth of approved products, gross margin profile by product and services mix, pipeline advancement and regulatory approvals, capacity utilization for manufacturing operations, and durability of royalty streams and partnerships that sustain cash flow visibility.
2. Valuation Analysis: Public Trading Comps & Multiples for RNA and Peptide Therapeutics Companies companies
2.1 - Public Peer Groups & Median Valuation Multiples for RNA and Peptide Therapeutics Companies sector
Comparable group 1: RNA and Peptide Therapeutics Companies
Everest Medicines
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative biopharmaceutical solutions focused on discovering, developing, manufacturing, and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs in Greater China and other Asia-Pacific markets. With a portfolio that includes oncology, immunology, cardio-renal diseases, and infectious diseases therapies, the company integrates licensing, clinical development, and commercialization to deliver next-generation treatments.
- Key Products:
- Oncology Therapies: Cutting-edge treatments for various cancers
- Immunology Treatments: Advanced therapies for autoimmune conditions
- Cardio-renal Drugs: Innovative solutions for cardiovascular and renal diseases
- Infectious Disease Medications: Next-generation treatments for bacterial and viral infections
- Vaccine Production: Development and manufacturing of transformative vaccines.
Pharma Mar
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of biopharmaceutical solutions focused on researching, developing, and commercializing oncology treatments derived from marine sources, aimed at improving the lives of patients with serious illnesses.
- Key Products:
- Yondelis®: Treatment for advanced soft tissue sarcoma and ovarian cancer
- Zepzelca®: Therapy for small-cell lung cancer
- Aplidin®: Antiviral agent for treating COVID-19 and other viral infections
- Molecular Diagnostics: Testing for infectious diseases, including COVID-19
- Genetic Analysis: Services for genetic analysis and paternity testing.